• Proceedings of the PSK Conference
• /
• 2003.10b
• /
• pp.119.2-119.2
• /
• 2003

Exposure of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) causes a variety of biological and toxicology effects, most of which are mediated by aryl hydrocarbon receptor (AhR). The ligand-bound AhR as a heterodimer with AhR nuclear translocator (ARNT) binds to its specific DNA recognition site, the dioxin-responsive element (DRE), and it results in increased transcription of CYP1A1 gene. Retinoic acid (RA) regulates the transcription of various genes for several essential functions through binding to two classes of nuclear receptors, the retinoic acid receptor (RAR) and retinoid X receptor (RXR). (omitted)

• Environmental Mutagens and Carcinogens
• /
• v.24 no.2
• /
• pp.51-66
• /
• 2004

Retinoids, better known as vitamin A, have been reported to inhibit the growth of several breast cancer cell lines in culture and to reduce breast tumor growth in animal models. Furthermore, retinoids can augment the action of other breast cancer cell growth inhibitors both in vitro and in vivo. Clinically, interest has increased in the potential use of retinoids for the prevention and treatment of human breast cancer. We have examine the effect of all-trans retinoic acid(tRA) and 9-cis retinoic acid(9-cis RA) on human breast cancer cell(MCF-10A, T47-D, MCF-7) proliferation using MTT assay and cell cycle analysis(FACS). Overexpression of cyclin D1 protein is observed in the majority of breast cancers, suggesting that dysregulated expression of cyclin D1 might be a critical event in breast cancer carcinogenesis. We investigated whether tRA and 9-cis RA might affect expression of cyclin D1 on human breast cancer cells(MCF-10A, T47-D, MCF-7) using RT-PCR and west-ern bolt. In MCF-10A cells, either tRA or 9-cis RA treatment did not affect the cell proliferation. In T47-D cells and MCF-7 cells, either tRA or 9-cis RA treatment showed the inhibition of the cell proliferation over control cells and also inhibit the estrogen stimulated cell proliferation when it was given together with estrogen. The effect of retinoids was dose- and time- dependent. T47-D cells treated with 1.0 $\muM$ tRA undergo G0/G1-phase arrest by Day 5. MCF-7 cells treated with 1.0 $\muM$ tRA undergo S-phase arrest by Day 5. All-trans retinoic acid(tRA) and 9-cis retinoic acid(9-cis RA) inhibited the cyelin D1 mRNA and protein expression levels of human MCF-7 and T47-D breast carcinoma cells in vitro. The data indicate that retinoids can reduce cyclin D1 expression levels in a variety of breast cell lines in vitro and result in inhibition of cell proliferation. tRA-mediated growth inhibition and cyclin D1 expression inhibition is more potent than 9-cis RA mediated that. tRA-mediated inhibition effect is more potent on T47-D cells than on MCF-7 cells. Our data suggest that retinoids activity is different according to property of cell lines. Future chemoprevention of breast cancer studies using retinoids will be necessary to determine the mechanism of the retinoids-mediated growth inhibition.

• Proceedings of the Korea Environmental Mutagen Society Conference
• /
• 2003.10a
• /
• pp.136-136
• /
• 2003

• Environmental Mutagens and Carcinogens
• /
• v.8 no.1
• /
• pp.47-55
• /
• 1988

발생중인 계배의 날개형성에 미치는 retinoic acid(RA)의 효과를 알아보았다. RA처리는 날개원기의 전단부로 부처 거울상을 띤 지골의 복제를 유발하였다. 이러한 RA처리에 따른 지골의 복제 효과는 발생시기 및 처리량에 의존적이었다. 즉 stage 18시기의 날개원기에 RA를 처리했을 때 최대의 지골 복제 효과가 유발되었으며, 20mg/ml 의 RA 용액으로 처리했을 때 최대의 지골 복제 효과가 나타났다. 이러한 실험결과는 RA 처리가 날개원기 세포의 positional value를 전후축 상에서 후위화하기 때문에 나타나는 것으로 해석될 수 있으며, 후위화의 정도는 발생단계 및 처리량에 의존적임을 시사하고 있다.

• Proceedings of the Korean Biophysical Society Conference
• /
• 2002.06b
• /
• pp.46-46
• /
• 2002

Cdk5, a neuronal Cdc2-like kinase, exhibits a variety of functions in neuronal differentiation and neurocytoskeleton dynamics as well as neuronal degeneration and cell death. However, its role in retinoic acid (RA)-induced differentiation has not been reported yet. We newly found that RA treatment of SK-N-BE(2)C, human neuroblastoma, increased expression of Cdk5 concomitantly with a neuronal specific activator, p35.(omitted)

• Bulletin of Food Technology
• /
• v.23 no.4
• /
• pp.535-543
• /
• 2010

장관은 우리 몸에서 가장 넓은 표면적을 가지고 있으며, 외부로부터 침입하는 이물에 대항하여 면역세포의 배치가 필수적이다. 항원과 만난 적이 없는 naive lymphocyte는 임파절 등 2차 임파기관의 수지세포(dendritic cell)가 임파구에 항원을 제시할 때 레티노인산(retinoic acid)을 생산하여 제공함으로써, 소장 조직에 특이적으로 임파구가 호밍(homing)하는 능력을 부여한다. 한편, 장에 있어서는 식품항원에 대한 면역반응을 억제할 필요가 있는데, RA는 T세포의 기능분화를 억제하여 면역관용의 성립에도 관여함이 밝혀졌다.

• 대한생식의학회:학술대회논문집
• /
• 2006.06a
• /
• pp.168.1-168.1
• /
• 2006

• Proceedings of the Korea Environmental Mutagen Society Conference
• /
• 2004.11a
• /
• pp.142-142
• /
• 2004

• Proceedings of the Korea Environmental Mutagen Society Conference
• /
• 2004.05a
• /
• pp.99-99
• /
• 2004

• Journal of Pharmaceutical Investigation
• /
• v.31 no.3
• /
• pp.167-172
• /
• 2001

All-trans retinoic acid (ATRA), vitamin A acid, has been shown to exert anticancer activity in a number of types of cancers, particularly in acute promyelocytic leukaemia (APL). Due to its highly variable bioavailability and induction of its own metabolism after oral treatment, development of parenteral dosage forms are required. However, its poor aqueous solubility and chemical unstability give major drawbacks in parenteral administration. This study was undertaken to investigate a possibility to develop a parenteral formulation of ATRA by employing solid lipid nanoparticle (SLN) as a carrier. By optimizing the production parameters and the composition of SLNs, SLNs with desired mean particle size (<100 nm) as a parenteral dosage form could be produced from trimyristin (as solid lipid), Egg phosphatidylcholine and Tween 80 (as SLN stabilizer). The mean particle size of SLN formulation of ATRA was not changed during storage, suggesting its physical stability. Thermal analysis confirmed that the inner lipid core of SLNs exist at solid state. The mean particle size of ATRA-loaded SLNs was not significantly changed by the lyophilization process. ATRA could be efficiently loaded in SLNs, while maintaining its anticancer activity against HL-60, a well-known APL cell line. Furthermore, by lyophilization, ATRA loaded in SLN could be retained chemically stable during storage. Taken together, our present study demonstrates that physically and chemically stable ATRA formulation adequate for parenteral administration could be obtained by employing SLN technology.